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Expansion of neopterin and beta2-microglobulin in cerebrospinal 
fluid reaches maximum levels early and late in the course of human 
immunodeficiency virus infection 
J.R. Bogner, B. Junge-Hülsing, U . Kronawitter, I . Sadri, A. Matuschke, and F.-D. Goebel 
Medizinische Pol ik l in ik der Univers i tä t M ü n c h e n 
Summary. Elevated cerebrospinal fluid (CSF) lev­
els of neopterin and beta2-microglobulin (/?2MG) 
reflect activation of the cellular immune response 
in the central nervous system (CNS). In 118 con­
secutive subjects [15 controls and 103 patients with 
human immunodeficiency virus (HIV) infection 
classified according to the Walter Reed staging sys­
tem (WR)], neopterin and ß2MG were determined 
in paired samples of CSF and serum. The perme­
ability of the blood-CSF barrier and local release 
of neopterin and ßlMG were taken into account: 
The molecular weight and diameter were used to 
determine filtration at the blood-CSF barrier. CSF 
neopterin levels were increased in all stages of HIV 
infection. ß2MG levels were elevated in WR2 and 
later stages. Neopterin, /J2MG, and cell counts 
similarly showed peaks in WR2, as did neopterin 
and /J2MG also in the later stages WR5 and WR6. 
Neurologically asymptomatic patients exhibited 
higher neopterin CSF levels than did controls 
(12.67 + 11.6 vs. 2.34+1.05 nmol/1, P<0.001) and 
higher CSF ß2MG (2.12 + 1.25 vs. 1.3 + 0.37 mg/1, 
Ρ = 0.001). Patients with HIV encephalopathy had 
higher levels of ß2MG (3.75 +1.83 mg/1) than 
asymptomatic patients (P<0.01). CSF levels of 
neopterin were markedly different in patients with 
HIV encephalopathy and toxoplasmosis (P<0.01). 
A high quantity of local release of the markers 
neopterin and ß2MG may reflect HIV infection 
of the CNS in early and late stages and additional 
release upon opportunistic infections. 
Key words: Human immunodeficiency virus infec­
tion - Neopterin - Beta2-microglobulin - Cerebro­
spinal fluid - Cerebral toxoplasmosis 
Abbreviations: A I D S = acquired immunodeficiency syndrome; 
/?2MG = beta 2 -microglobul in ; CNS = central nervous system; 
CSF = cerebrospinal fluid; H I V = human immunodeficiency v i ­
rus (type I ) ; R I A = radioimmunoassay; SD = standard devia­
t i on ; S E M = standard error o f the mean; W R = Walter Reed 
(staging classification); E L I S A = enzyme-linked immunosor­
bent assay 
Patients with early asymptomatic human immuno­
deficiency virus (HIV) infection often present with 
an inflammatory reaction of the cerebrospinal fluid 
(CSF), while apparent neurological symptoms are 
missing [2, 8, 19]. Cell count, albumin levels, neop­
terin and beta2-microglobulin (ß2MG) levels have 
been reported to be elevated in asymptomatic HIV 
infection [15, 19]. 
Neopterin is produced by macrophages after 
stimulation with gamma-interferon during activa­
tion of the cell-mediated immune response [18, 19]. 
Serum concentrations of neopterin are elevated in 
HIV infection and have been demonstrated to con­
vey prognostic information [1 , 5]. Increased levels 
of neopterin have been found in patients with acute 
aseptic meningoencephalitis and during serocon­
version to HIV [4]. 
Elevated levels of ß2MG reflect activation of 
the cellular immune response and an increased 
turnover of cell membranes. High CSF levels have 
been detected in patients with acute viral infections 
of the central nervous system (CNS) [15, 20] and 
in subjects with myeloproliferative disease with 
CNS involvement [14]. 
In an attempt to attain a more detailed descrip­
tion of the natural course of immune activation 
in the CNS, we started to determine neopterin and 
ß2MG levels according to stages of the Walter 
Reed (WR) staging classification [16]. Another aim 
was to compare the CSF levels in patients with 
HIV encephalopathy (term used synonymously 
with HIV dementia complex) in contrast with cere­
bral toxoplasmosis. Minor impairment of the 
blood-CSF barrier has been reported in HIV infec­
tion and HIV encephalopathy [2, 6]. The perme­
ability of the blood-CSF barrier and local release 
of neopterin and ß2MG were estimated: The mo­
lecular weight and diameter were used to determine 
the expected filtration at the blood-CSF barrier 
and intracerebral production. We also calculated 
CSF/serum albumin quotients in order to estimate 
the range of barrier disorder. 
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Methods 
Our study comprised 118 subjects, including 
15 control subjects recruited from a group of HIV-
1 antibody negative patients with noninflamma­
tory CNS disease (age-matched). Eight patients 
were classified as WR stage 1 (WR1), 17 as WR2, 
10 as WR3, 12 as WR4, 15 as WR5, and 41 as 
WR6. Neurological evaluation included a detailed 
history and neurological examination in all pa­
tients. Patients were enrolled consecutively. Neu­
rological symptoms were not regarded as an inclu­
sion criterion. Informed consent was obtained 
from all patients undergoing lumbar puncture. In 
neurologically symptomatic patients, radiologic 
imaging techniques (computed tomography and/or 
magnetic resonance depending on clinical findings) 
were performed as indicated by the clinical find­
ings. 
HIV encephalopathy was diagnosed when ma­
jor disabling neuropsychological signs according 
to the Centers for Disease Control (CDC) defini­
tion were found. The diagnosis required thorough 
exclusion of opportunistic manifestations. Neop­
terin (radioimmunoassay, RIA, Henning, FRG), 
ß2MG (enzyme-linked immunosorbent assay, EL-
ISA, Pharmacia, Sweden), and albumin were deter­
mined in paired samples of CSF and serum. Cell 
counts were taken from the first portion of the 
CSF after lumbar puncture. Statistical evaluation 
was performed by /-tests and analysis of variance. 
Differences were regarded as significnt i f Ρ < 0.05 
[3]. 
Results 
To estimate the intrathecal production of neopterin 
and /?2MG, we calculated the filtration according 
to the barrier concept by K. Felgenhauer [7]. 
Neopterin has a molecular weight of 253.2 
(C9HHN5O4) daltons. The estimated maximum 
hydrodynamic radius of this neutral compound is 
extrapolated to 6.5 Ä (Dr. Nau, Göttingen, pers. 
comm., extrapolation of filtration rate of small 
molecules). The resulting serum/CSF distribution 
in a steady-state equilibrium therefore can be as­
sumed to be a quotient of 40/1 [8]. Thus, 1/40 
(2.5%) of the neopterin CSF concentration origi­
nates from serum, whereas the rest (97.5%) origi­
nates from the CNS ("corrected CSF neopterin"). 
j?2MG has a molecular weight of 16900 dal­
tons. The serum/CSF equilibrium for small pro­
teins (=>20 Ä) is in the range of 100 or above [6]. 
Thus, less than 1 % of the CSF jS2MG is expected 
to originate from the blood. 
Neopter in in CSF ( n m o l / l ) ± SEM 
CTRL WR 1 WR 2 WR 3 WR 4 WR 5 WR 6 
(n=15) ( n = 8) (n=17) (n=10) (n=12) (n=15) (n = 41) 
Fig. 1. Corrected neopterin level in cerebrospinal fluid (CSF) 
( = CSF neopterin minus 2.5% o f CSF neopterin) according 
to the stages o f the Walter Reed ( W R ) staging classification. 
C T R L = controls; S E M = standard error o f the mean; * P< 
0.05; ** P<0M 
Neopter in 
Ratio C S F / s e r u m ± SEM 
CTRL WR 1 WR 2 WR 3 WR 4 WR 5 WR 6 
(n = 15) (n = 8) (n = 17) (n=10) (n=12) (n=15) (n = 4 l ) 
Fig. 2. CSF/serum ratio o f neopterin according to the stages 
o f the W R staging classification. * .P<0.05 
CSF parameters according to WR stages 
Corrected neopterin CSF levels were computed us­
ing the following formula: Neo Corr = neopterin 
in CSF minus 2.5% of neopterin in CSF. As com­
pared with controls, the corrected CSF neopterin 
levels were elevated in all stages of HIV infection 
(WR1 versus controls with standard deviation: 
7.02 + 3.98 vs 2.34+1.05 nmol/l; Ρ < 0.05). 
As shown in Fig. 1, the average level of CSF 
neopterin expands in WR2 but declines again in 
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/ ^ - M i c r o g l o b u l i n in CSF ( m g / l ) ± SEM 
4.0 •·, 
CTRL WR 1 WR 2 WR 3 WR 4 WR 5 WR 6 
(n=15) (n = 8) (n=10) (n=12) (n=15) (n = 41) 
Fig. 3. Beta 2 -microglobul in (ß2MG) in CSF according to the 
stages o f the W R staging classification. * Ρ < 0.05; ** Ρ< 0.01 
β2 - Microglobul in 
Ratio C S F / s e r u m ± SEM 
CTRL WR 1 WR 2 WR 3 WR 4 WR 5 WR 6 
(n=15) (n = 8) (n=17) (n=10) (n=12) (n = 15) (n = 4 l ) 
Fig. 4. j52MG in CSF and CSF/serum ratio according to the 
stages o f the W R staging classification. * Ρ< 0.05 
Table 1. Cell count and total protein according to stages o f the W R staging classification 
C T R L W R 1 W R 2 W R 3 W R 4 W R 5 W R 6 
(" = 15) (« = 8) ( « = 1 7 ) (/i = 10) (/i = 1 2 ) ( " = 1 5 ) (/ι = 41) 
Cell count (1/3) 5.3 + 3.8 * 1 3 . 5 ± 1 4 . 7 37.8 + 39.8 41.8 + 43.8 18.5+18.2 15.7+13.6 15.5 + 30.8 
Total protein (mg/dl) 3 3 . 7 ± 1 8 . 9 34.5 + 12.4 40.7 ± 1 5 . 5 40.9+14.1 3 3 . 7 ± 7.0 41.9 + 20.1 47.3 ± 2 2 . 6 
* / 3 < 0 . 0 5 
WR3 and WR4. In the later stages WR5 and WR6, 
a significant increase of neopterin in the CSF and 
the ratio was observed (Fig. 1). 
Quotients of CSF/serum neopterin increased 
significantly from controls (0.36 + 0.16) to WR1 
(0.51+0.22) and from WR1 to WR2 (1.03 + 1.01 
Ρ < 0.05; Fig. 2). 
According to molecule size (see above) and ex­
pected filtration estimates, 1 % or less of the mea­
sured CSF ß2MG is filtered from the serum to 
CSF. Albumin serum/CSF quotients ranged from 
2.3 χ 10~ 3 to 12.6 χ 10" 3 . Mean albumin quotients 
were 4.21 χ 10" 3 in WR1 ( + 2.73 χ 10" 3 ) and 
7.1 χ 10" 3 in WR6 ( + 6.86χ 10~ 3 ; NS). 
Thus, in WR6, the maximum increase of filtered 
ß2MG in the CSF would not even double the se­
rum portion of j?2MG measured in the CSF (from 
1% to 2%). Therefore, it seems acceptable to pos­
tulate that the actually measured CSF ß2MG level 
equals basically the corrected ß2MG taking into 
account the dysfunction of the blood-CSF barrier 
[which is not very pronounced in patients with 
full-blown acquired immunodeficiency syndrome 
(AIDS) and opportunistic CNS infection; the up­
per limit in our data was 12.6 χ 10" 3 ] . 
ß2MG CSF levels (Fig. 3) showed no significant 
difference between WR1 and controls (1.30 + 0.74 
vs 1.27 + 0.37 mg/l), while there was a rise in WR2 
(2.2 + 0.77 mg/l, Ρ < 0.05). A further expansion oc­
curred from WR4 to WR5 (1.9 + 0.8 vs 3.4+1.68 
mg/l; Ρ<0.01). The ratio CSF/serum of jff2MG 
was lower in WR1 than in controls (0.49 + 0.25 
vs 0.74 + 0.24; Ρ< 0.05). From WR1 to WR6 the 
ratio paralleled the two peaks for ß2MG in WR2 
as well as in WR5 and WR6 (Fig. 4). 
Cell counts were elevated significantly com­
pared with controls in all stages of HIV infection 
(Table 1). Albumin concentrations in the CSF 
reached a maximum in WR 6 (47.3 mg/l; Table 1). 
CSF parameters according to neurological diagnosis 
Neurologically asymptomatic patients showed 
higher levels for neopterin in the CSF (corrected) 
than did controls (12.67 + 11.6 vs 2.34 + 1.05 nmol/ 
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Table 2. Corrected CSF neopterin ( = CSF neopterin minus 2.5% o f CSF neopterin) and CSF ß2MG and CSF/serum ratios, 
cell count, and total protein according to neurologic diagnosis in HIV-infected patients and controls (total patient number lower 
than 118 because o f missing or uncertain diagnoses) 
Controls Asymptomatic H I V encepha- Cerebral toxo­ Toxoversus 
HIV-infected lophathy plasmosis asymptomatic 
(n=15) (/ι = 45) (/ι = 15) (n = 9) individuals 
Corrected 2 34 *** 12.67 21.40 * 73.90 * 
CSF neopterin ± 1 . 0 5 11.6 ± 2 0 . 4 61.3 
(nmol/ l ) 
Q neopterin 0.36 *** 0.71 0.64 1.29 
(CSF/serum) ± 0 . 1 6 ± 0 . 6 3 ± 0 . 3 7 ± 1 . 3 0 
CSF ß2MG 1 30 *** 2.12 ** 3.75 ** 4.42 ** 
(mg/1) ± 0 . 3 7 ± 1 . 2 5 ± 1 . 8 3 ± 1 . 9 4 
Q 0 2 M G 0.74 0.63 0.91 1.13 
(CSF/serum) ± 0 . 2 5 ± 0 . 3 2 ± 0 . 5 3 ± 1 . 1 0 
Cell count 15.7 27.8 16.3 15.5 
(1/3 cells) ± 1 3 . 6 ± 2 6 . 5 ± 1 3 . 6 ± 3 0 . 8 
Total protein 33.7 37.3 41.7 63.2 
(mg/dl) ± 1 8 . 9 18.6 ± 3 2 . 5 ± 8 5 . 2 
Q = quotient; * P < 0 . 0 5 ; ** P < 0 . 0 1 ; *** /><0.001 
1; /><0.001). Similarly, ß2MG in the CSF was sig­
nificantly expanded in HIV-infected subjects as 
compared with controls (2.12 ±1.25 vs 1.3 ± 
0.37 mg/1; Ρ < 0.001; Table 2). Patients with HIV 
encephalopathy (diagnosis by clinical evaluation 
and exclusion of opportunistic manifestation) 
showed higher levels of neopterin in the CSF 
(21.4 + 20.4 nmol/l; NS vs asymptomatic subjects) 
and ß2MG (3.75 + 1.83 mg/1; Ρ<0.01 vs asympto­
matic subjects). 
In patients with cerebral toxoplasmosis the av­
erage (corrected) CSF level of neopterin was 
75.8 + 62.8 nmol/l, ranging significantly higher 
than in asymptomatic subjects and patients with 
HIV encephalopathy (P<0.05). 
ß2MG in the CSF was markedly elevated in 
cerebral toxoplasmosis (P<0.01; Table 2). 
Discussion 
Increased CSF levels of neopterin and ß2MG have 
been reported in inflammatory neurologic disease, 
aseptic meningitis [20], Lyme borreliosis [4], 
measles [15], multiple sclerosis [20], neoplastic dis­
ease, and subarachnoid hemorrhage [13]. In indi­
viduals with HIV infection, intrathecal production 
of neopterin and ß2MG is detectable in the CSF 
[6, 7]. In comparison with normal subjects, HIV-
infected patients show significantly increased levels 
of neopterin and ß2MG. 
Earlier investigations by Fuchs et al. [9] and 
Sönnerborg et al. [18, 19] suggested a rise in neop­
terin and ß2MG levels in the CSF according to 
clinical staging: aymptomatic HIV infection, 
lymphadenopathy syndrome, AIDS-related com­
plex, and AIDS, respectively. Our data show that 
the increase of neopterin an /J2MG levels is not 
a continuum with respect to the stages of the WR 
staging classification. Rather, we find an early and 
a late expansion (Figs. 1-4). 
The expansion of immunologic activation pa­
rameters in the early phases of HIV infection may 
be taken as an indirect sign of early CNS involve­
ment, even though the patients may remain neu­
rologically asymptomatic. Sönnerberg and co­
workers found the highest CSF levels of neopterin 
and /?2MG in patients in whom they successfully 
isolated HIV-1 from the CSF [19]. They found 
a ratio of CSF/serum of over 1.0 in patients with 
AIDS dementia complex. The mean ratio in our 
patients with this diagnosis was 0.73 for neopterin 
and 0.94 for /J2MG, again suggesting an intrathe­
cal production by an activated immune system. In 
both parameters, a wide range of individual values 
contributed to a high variation. 
One aim of our study was the comparison of 
CSF activation parameters in different clinical set­
tings. Patients with overt neuropsychiatric symp­
toms like impairment of memory function, concen­
tration, and coordination require a thorough diag­
nostic work-up. The diagnosis of HIV encephalo­
pathy can only be made after the exclusion of op­
portunistic manifestations. A diagnostic tool ad­
ministrated by a spinal tap would be of impor­
tance. The hypothesis that CSF neopterin and 
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ß2MG might be significantly different in patients 
with either HIV encephalopathy or opportunistic 
infections could be confirmed by our data for the 
diagnosis of cerebral toxoplasmosis. 
The high levels of intrathecally produced neop­
terin and ß2MG in HIV infection and neuro-AIDS 
may reflect an early infection and activation of 
cerebral compartments, e.g., cells of the microglia 
and imported macrophages. Current investigations 
in our group are concentrating on the measure­
ment of neopterin in culture supernatants of micro­
glia and astrocytoma cell lines infected with H I V 
CSF neopterin and ß2MG levels are parameters 
which reflect early CNS involvement in HIV infec­
tion. Mean maximum absolute levels and quotients 
(CSF/serum) are found in early and late stages of 
HIV infection. 
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